文献速递细菌感染、耐药与抗菌药物

新型β-内酰胺/β-内酰胺酶抑制剂组合对产丝氨酸碳青霉烯酶碳青霉烯耐药铜绿假单胞菌的活性

Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

该研究通过ERACE-PA全球监测收集碳青霉烯耐药铜绿假单胞菌,比较头孢他啶/阿维巴坦、头孢他啶、亚胺培南/瑞来巴坦、亚胺培南、美罗培南/伐博巴坦和美罗培南对产丝氨酸碳青霉烯酶菌株的体外活性。结果显示头孢他啶/阿维巴坦敏感性最高(91%),美罗培南/伐博巴坦活性差(6%敏感),与美罗培南单药相似(3%敏感)。

要点

  • 头孢他啶/阿维巴坦对产丝氨酸碳青霉烯酶铜绿假单胞菌敏感性达91%,MIC50/90为4/8 mg/L。
  • 亚胺培南/瑞来巴坦对产KPC菌株敏感性38%,对亚胺培南为0%。
  • 美罗培南/伐博巴坦敏感性仅6%,与美罗培南单药(3%)相似。

核心结论

  • 在新型β-内酰胺/β-内酰胺酶抑制剂组合中,头孢他啶/阿维巴坦体外活性较好,是产丝氨酸碳青霉烯酶铜绿假单胞菌的合理治疗选择。
  • 亚胺培南/瑞来巴坦显示一定活性,尤其对产blaKPC菌株;美罗培南/伐博巴坦活性差,MIC与美罗培南单药相似。

研究设计与样本

  • 通过ERACE-PA全球监测收集碳青霉烯耐药铜绿假单胞菌,评估丝氨酸碳青霉烯酶阳性分离株。
  • 采用肉汤微量稀释法测定各新型β-内酰胺/β-内酰胺酶抑制剂组合及单药的MIC。

主要发现

  • GES是最常见的碳青霉烯酶(n=59),其次为KPC(n=8)。
  • 头孢他啶/阿维巴坦MIC50/MIC90为4/8 mg/L,91%菌株敏感;头孢他啶单药仅3%敏感。
  • 亚胺培南/瑞来巴坦MIC50/MIC90为16/>16 mg/L,13%菌株敏感;产KPC菌株中38%对亚胺培南/瑞来巴坦敏感,对亚胺培南为0%。
  • 美罗培南/伐博巴坦MIC50/MIC90为>16/>16 mg/L,6%菌株敏感;美罗培南单药MIC50/90为>8/>8 mg/L,3%敏感。

临床怎么用

  • 作者认为,头孢他啶/阿维巴坦是产丝氨酸碳青霉烯酶铜绿假单胞菌的合理治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Antimicrobial resistance in Pseudomonas aeruginosa is complex and multifaceted. While the novel β-lactamase inhibitors (BLIs) avibactam, relebactam and vaborbactam inhibit serine-based β-lactamases, the comparative potency of the novel β-lactam (BL)/BLI combinations against serine carbapenemase-producing P. aeruginosa is unknown. OBJECTIVES: To compare the in vitro activity of ceftazidime/avibactam, ceftazidime, imipenem/relebactam, imipenem, meropenem/vaborbactam and meropenem against serine β-lactamase-producing P. aeruginosa. METHODS: Carbapenem-resistant P. aeruginosa were collated through the Enhancing Rational Antimicrobials against Carbapenem-resistant P. aeruginosa (ERACE-PA) Global Surveillance. Isolates positive for serine-based carbapenemases were assessed. MICs were determined by broth microdilution to each novel BL/BLI and BL alone. RESULTS: GES was the most common carbapenemase identified (n = 59) followed by KPC (n = 8). Ceftazidime/avibactam had MIC50/MIC90 values of 4/8 mg/L and 91% of isolates were susceptible. Conversely, ceftazidime alone was active against only 3% of isolates. The MIC50/MIC90 of imipenem/relebactam were 16/>16 mg/L and 13% of all isolates were defined as susceptible. Of the KPC-producing isolates, 38% were susceptible to imipenem/relebactam, compared with 0% to imipenem. The meropenem/vaborbactam MIC50/MIC90 were >16/>16 mg/L, and 6% of isolates were susceptible, which was similar to meropenem alone (MIC50/90, >8/>8 mg/L; 3% susceptible) suggesting the addition of vaborbactam cannot overcome co-expressed, non-enzymatic resistance mechanisms. CONCLUSIONS: Among the novel BL/BLIs, ceftazidime/avibactam displayed better in vitro activity and thus is a rational treatment option for serine carbapenemase-harbouring P. aeruginosa. While imipenem/relebactam displayed some activity, particularly against isolates with blaKPC, meropenem/vaborbactam exhibited poor activity, with MICs similar to meropenem alone.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Lee SY, Gill CM, Nicolau DP, et al. Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2023. PMID: 37840005. doi:10.1093/jac/dkad225

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。